ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

Renal Cell Carcinoma

Renal Cell Carcinoma

A new study has found a series of potential microRNA biomarkers that could predict tyrosine kinase inhibitor response in RCC patients.

Both African-American and Caucasian patients with advanced RCC have seen improved survival with targeted therapies, though African-Americans still experience survival disadvantages.

In this video we discuss the continuation of nivolumab after tumor progression in patients with advanced renal cell carcinoma in the CheckMate 025 trial.

Long-term follow-up of a phase I and a phase II study shows that nivolumab produces strong overall survival benefit in patients with advanced renal cell carcinoma.

Patients with metastatic RCC who undergo cytoreductive nephrectomy plus targeted therapy have better survival over those treated only with targeted therapy.

Cabozantinib significantly improved the overall survival of patients with previously treated advanced RCC, according to the second interim analysis of the METEOR trial.

Despite improved understanding of the molecular features of renal tumors, increasing expertise in surgical management of localized renal cancers, and multiple effective systemic therapies for metastatic cancer, mortality from renal cell carcinoma remains largely unchanged.

Pages

Subscribe to Renal Cell Carcinoma on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.